AEON BIOPHARMA INC (AEON) Stock Price & Overview
NYSEARCA:AEON • US00791X2099
The current stock price of AEON is 1.09 USD. Today AEON is down by 0%. In the past month the price decreased by -6.84%. In the past year, price increased by 65.13%.
AEON Key Statistics
- Market Cap
- 40.499M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.98
- Dividend Yield
- N/A
AEON Stock Performance
AEON Stock Chart
AEON Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AEON. When comparing the yearly performance of all stocks, AEON is one of the better performing stocks in the market, outperforming 93.51% of all stocks.
AEON Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEON. AEON has a bad profitability rating. Also its financial health evaluation is rather negative.
AEON Earnings
AEON Forecast & Estimates
8 analysts have analysed AEON and the average price target is 5.3 USD. This implies a price increase of 386.61% is expected in the next year compared to the current price of 1.09.
AEON Financial Highlights
Over the last trailing twelve months AEON reported a non-GAAP Earnings per Share(EPS) of -5.98. The EPS increased by 99.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AEON Ownership
About AEON
Company Profile
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
Company Info
AEON BIOPHARMA INC
4040 Macarthur Boulevard, Suite 310
Newport Beach CALIFORNIA US
Employees: 6
Phone: 19492844555.0
AEON BIOPHARMA INC / AEON FAQ
Can you describe the business of AEON BIOPHARMA INC?
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
What is the stock price of AEON BIOPHARMA INC today?
The current stock price of AEON is 1.09 USD.
Does AEON stock pay dividends?
AEON does not pay a dividend.
What is the ChartMill rating of AEON BIOPHARMA INC stock?
AEON has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about AEON BIOPHARMA INC (AEON) stock?
8 analysts have analysed AEON and the average price target is 5.3 USD. This implies a price increase of 386.61% is expected in the next year compared to the current price of 1.09.
What is the Short Interest ratio of AEON BIOPHARMA INC (AEON) stock?
The outstanding short interest for AEON BIOPHARMA INC (AEON) is 2.04% of its float.